| pubmed-article:17492399 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0020205 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0494165 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0555952 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:17492399 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:17492399 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17492399 | pubmed:dateCreated | 2007-8-7 | lld:pubmed |
| pubmed-article:17492399 | pubmed:abstractText | Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2-63) and the median overall survival (OS) 21 months (range 6-63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached. | lld:pubmed |
| pubmed-article:17492399 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17492399 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17492399 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17492399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17492399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17492399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17492399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17492399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17492399 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17492399 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17492399 | pubmed:issn | 0167-6997 | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:SantoroArmand... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:DociRobertoR | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:MarconIlariaI | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:CarnaghiCarlo... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:PediciniVitto... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:RimassaLorenz... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:GarassinoIsab... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:GulloGiuseppe... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:MorenghiEmanu... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:RosatiRiccard... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:AbbadessaGiov... | lld:pubmed |
| pubmed-article:17492399 | pubmed:author | pubmed-author:ZuradelliMoni... | lld:pubmed |
| pubmed-article:17492399 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17492399 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:17492399 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17492399 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17492399 | pubmed:pagination | 479-85 | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:meshHeading | pubmed-meshheading:17492399... | lld:pubmed |
| pubmed-article:17492399 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17492399 | pubmed:articleTitle | The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. | lld:pubmed |
| pubmed-article:17492399 | pubmed:affiliation | Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano (Milano), Italy. carlo.carnaghi@humanitas.it | lld:pubmed |
| pubmed-article:17492399 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17492399 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17492399 | lld:pubmed |
